FDA Recalls 5,460 Cartons of Blood Thinner Pradaxa Over Impurity Levels

The FDA has recalled 5,460 cartons of the blood thinner dabigatran etexilate, sold under the brand name Pradaxa, after stability testing turned up impurity levels above acceptable limits.

That works out to 299,520 capsules pulled from the supply chain, according to NTD. The drug was manufactured by Alkem Laboratories, based in Mumbai, India, and distributed nationwide by Major Pharmaceuticals of Indianapolis, according to the FDA notice cited by both NTD and the Epoch Times.

The problem showed up during routine 12-month stability testing, the kind of check the FDA requires to make sure a drug still meets spec throughout its shelf life. Testing found elevated levels of what the FDA labeled Impurity II, Impurity III, and total impurities beyond the accepted threshold. The agency's notice, as reported by the Epoch Times, did not identify what those impurities actually are.

Patients deserve to know what compound is showing up above spec in a drug they're putting in their body every day, not just a code name. The FDA has not classified the severity of this recall as of Wednesday, meaning it hasn't yet said whether this poses a serious health risk or a more minor quality issue.

Three lots are named in the recall, all expiring April 30, 2027: lot 25141583 (150 mg capsules, 60-count), lot 25141585 (75 mg capsules, 60-count), and lot 25141586 (75 mg capsules, 30-count). Patients with any of these bottles should check the lot number against their packaging.

Dabigatran is a direct oral anticoagulant, prescribed to cut the risk of stroke and blood clots in people with atrial fibrillation, and to prevent or treat deep vein thrombosis and pulmonary embolism, including after hip replacement surgery, according to the Mayo Clinic. When it hit the market in 2010, dabigatran was the first drug of its kind marketed as an alternative to warfarin, which requires regular blood monitoring that dabigatran doesn't.

The CDC estimates up to 900,000 Americans are affected by blood clots annually, and roughly three in ten people who suffer one will have another within a decade. Every outlet covering this, including rejoyhealth, is hammering the same warning: do not stop taking a blood thinner cold turkey because of a recall headline. Abruptly quitting anticoagulant therapy can spike your risk of a dangerous clot. Call your doctor or pharmacist first.

Alkem Laboratories did not respond to requests for comment from either the Epoch Times or NTD by publication time. No statement from the company appears in any of the current reporting.

This isn't Alkem's first quality control issue in 2025 and 2026. The Epoch Times notes the company recalled more than 17,000 bottles of metoprolol succinate extended-release tablets in May over a "dissolution failure," and in September 2025 pulled more than 140,000 bottles of generic atorvastatin for a similar issue. Three recalls tied to manufacturing quality inside roughly a year represents a pattern worth monitoring.

It's also not the first time dabigatran itself has had impurity trouble. NTD points out that Ascend Laboratories issued a nationwide recall of generic dabigatran etexilate capsules in March 2023 after finding elevated levels of a nitrosamine impurity called N-Nitroso-dabigatran. Nitrosamines occur naturally in some foods and water, but regulators treat elevated levels in medication as a red flag requiring action.

No injuries or adverse events tied to this specific 2026 recall have been reported in any of the available FDA notices or news coverage so far. The FDA says it continues to monitor the situation.

The FDA has not classified the recall's risk level, and neither the agency's notice nor the company has specified what Impurity II and Impurity III actually are chemically or at what concentration they were detected. Until the FDA issues that classification, or Alkem responds publicly, patients holding these lot numbers have one clear instruction from every source: talk to your pharmacist before you do anything else.